Analyze the information and social media posts to determine if the closing price of $bmy will ascend or descend at 2017-03-07. Please respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-02-21,-0.7,4.4,-2.5,0.3,0.3,-0.6,-3.0,-4.8,-6.6,-5.7,-3.9
2017-02-22,0.3,2.0,-0.1,1.0,1.0,-1.0,-3.4,-5.1,-6.9,-6.8,-5.1
2017-02-23,-0.3,0.6,-1.3,0.8,0.8,-1.5,-3.4,-5.0,-7.1,-7.5,-6.1
2017-02-24,-0.9,0.1,-1.0,1.2,1.2,-1.9,-3.7,-5.4,-7.3,-8.5,-7.2
2017-02-27,-0.1,0.8,-0.6,0.2,0.2,-1.4,-3.0,-5.0,-6.8,-8.2,-7.4
2017-02-28,-0.3,0.4,-0.9,0.3,0.3,-1.0,-2.4,-4.5,-6.3,-8.0,-7.6
2017-03-01,-0.3,0.1,-1.2,0.8,0.8,-1.1,-2.6,-4.7,-6.4,-8.2,-8.3
2017-03-02,0.1,1.1,-0.5,-0.6,-0.6,-0.2,-1.8,-3.6,-5.2,-7.1,-7.8
2017-03-03,-0.9,0.1,-1.1,0.7,0.7,-0.6,-1.9,-3.6,-5.2,-7.1,-8.3
2017-03-06,0.1,0.5,-1.3,-0.5,-0.5,0.0,-1.0,-2.5,-4.2,-5.9,-7.4

2017-02-21: rt AT_USER i shorted $bmy AT_USER ichan loves to play both sides|rt AT_USER $bmy spiking 2.2% on dow jones report carl icahn has taken stake, sees bmy as possible takeover target|AT_USER i think $bmy 
2017-02-22: #bristolmyerssquibb bristol-myers squibb company earns "buy" rating from argus. read more:  $bmy|marketcurrents: allergan's saunders: no interest in valeant  $agn $vrx $bmy|allergan's saunders: no int
2017-02-23: $bmy technicals are ugly though|$bmy holding a lot of cash, could be handy in this shifting environment bullish AT_USER|AT_USER what about $agn $bmy?|AT_USER recent textbook example was $bmy on jan 20
2017-02-24: rt AT_USER clovis oncology, inc. $clvs gets news from fda, merrill lynch  $ibb $xbi $atra exel $tsro $celg $bmy¡­|clovis oncology, inc. $clvs gets news from fda, merrill lynch  $ibb $xbi $atra exel $t
2017-02-25: benzinga: carl icahn's track record in big pharma  $bmy $lly $biib $sny $agn $azn|carl icahn's track record in big pharma  $bmy $lly $biib $sny $agn $azn|rt AT_USER pharmalot.. pharmalittle.. good mor
2017-02-27: rt AT_USER biotech partnering is a many-splendored thing  $exel $bmy #cancer |biotech partnering is a many-splendored thing  $exel $bmy #cancer |biotech partnering is a many-splendored thing  $exel $b
2017-03-01: rt AT_USER AT_USER $nwbo p3 trial could be halted by AT_USER any day due to overwhelming efficacy as $bmy #opdivo has #checkmat¡­|$bmy bristol-myers squibb to present data that advances understanding 
2017-03-02: 5 things for #pharma #marketers to know: thurs., mar. 2 $pfe $jnj $mrk $bmy $lly #drugpricing #patients $nvo¡­ |rt AT_USER why did infinity pharmaceuticals, inc. $infi gain +20%?  $bmy #cancer #biotec
2017-03-03: why short sellers are making a massive bet in major pharma  $pfe $mrk $teva $bmy $abbv $lly |why short sellers are making a massive bet in major pharma  $pfe $mrk $teva $bmy $abbv $lly |$bmy is in bul
2017-03-04: rt AT_USER new features coming soon! free week demo:  #ascendtrader $spy $qqq $arwr $bmy $pot $snap $aapl $t¡­|rt AT_USER new AT_USER blank space use? $twtr $hlf $iep $myl $bmy $agn $spy $spx AT_USER 
2017-03-05: this writer is a liar! they did not say that! $agn myl $mrk $jnj $amgn $bmy $teva $ipxl $fb $prgo $nvs $sny $lly |insider buying steady as market again hits all-time highs  $arnc $jmba $musa $bmy $sm 
2017-03-06: bristol-myers squibb and innate pharma: innovation is never a single event  $azn $bmy $mrk $nvo $sny $iphyf|salphatrending: bristol-myers squibb (bmy) ceo giovanni caforio presents at cowen and compan
Answer:
Fall